DCIS - QUESTIONS

Clinical Case Conference UCSD Radiation Oncology SA-CME

1.	To be included in the low risk group in the ECOG DCIS trial a patient could have all of the following
	except?

- A) Grade 2 Disease
- B) 2.9 cm lesion
- C) ER positive disease
- D) 3mm margin
- E) Non-palpable lesion

2.	Patients enrolled in the UK Tamoxifen trial who did not get radiotherapy and did not get tamoxifen
	had a 10% ipsilateral recurrence rate of DCIS. What was the recurrence rate for patients that were
	randomized to tamoxifen only?

- A) 10%
- B) 8%
- C) 6%
- D) 4%
- E) 2%

3. What percentage of women discontinued treatment (tamoxifen or placebo) in the NSABP B-24 trial?

- A) 61%
- B) 51%
- C) 41%
- D) 31%
- E) 21%

4. Which of the following risk factors is not included in the USC/Van Nuys prognostic index (USC/VNPI)?

- A) Tumor size
- B) Margin width
- C) Age
- D) Histologic classification
- E) Hormone receptor status

5. NSABP B-43 is a trial examining the role of trastuzumab in the treatment of women with Her2neu+ DCIS. Approximately what percentage women enrolled on the trial were Her2neu+?

- A) 25%
- B) 35%
- C) 45%
- D) 55%
- E) 65%